Premium
Outcome of autologous hematopoietic stem cell transplantation in children and adolescents with relapsed or refractory Hodgkin's lymphoma
Author(s) -
Hazar Volkan,
Kesik Vural,
Aksoylar Serap,
Karakukcu Musa,
Ozturk Gulyuz,
Kupesiz Alphan,
Atas Erman,
Oniz Haldun,
Kansoy Savas,
Unal Ekrem,
Tanyeli Atila,
Erbey Fatih,
Elli Murat,
Tacyildiz Nurdan,
Karasu Gulsun Tezcan,
Kocak Ulker,
Anak Sema,
Yilmaz Bengoa Sebnem,
Sezgin Gulay,
Atay Didem,
Unal Emel,
Uygun Vedat,
Kurucu Nilgun,
Kaya Zuhre,
Yesilipek Akif
Publication year - 2015
Publication title -
pediatric transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.457
H-Index - 69
eISSN - 1399-3046
pISSN - 1397-3142
DOI - 10.1111/petr.12573
Subject(s) - medicine , hazard ratio , hematopoietic stem cell transplantation , melphalan , etoposide , transplantation , lymphoma , surgery , refractory (planetary science) , chemotherapy , gastroenterology , oncology , confidence interval , astrobiology , physics
This study evaluates the outcome of 66 pediatric patients with rr HL who underwent autoHSCT. Twenty‐nine patients experienced early relapse, and 19 patients experienced late relapse. Of 18 newly diagnosed with HL , 13 were primary refractory disease and five had late responsive disease. At the time of transplantation, only 68% of the patients were chemosensitive. The majority of patients received BCNU + etoposide + ara‐C + melphalan for conditioning (45/66), and peripheral blood (56/66) was used as a source of stem cells. After a median follow‐up period of 39 months, 46 patients were alive. At five yr, the probabilities of OS , EFS , the relapse rate, and the non‐relapse mortality rate were 63.1%, 54.3%, 36.4%, and 9.1%, respectively. The probability of EFS in chemosensitive and chemoresistant patients at five yr was 72.3% and 19%, respectively (p < 0.001). Multivariate analysis showed that chemoresistant disease at the time of transplantation was the only factor predicting limited both OS (hazard ratio = 4.073) and EFS (hazard ratio = 4.599). Auto HSCT plays an important role for the treatment of rr HL in children and adolescents, and survival rates are better for patients with chemosensitive disease at the time of transplantation.